Further research was done, and found the treatment did actually benefit babies in lower-income countries, too. The December 2020 version of the review stated that the "evidence [that the treatment saves babies] is robust, regardless of resource setting (high, middle or low)" and that further research should focus on "specific understudied subgroups such as multiple pregnancies and other high-risk obstetric groups, and the risks and benefits in the very early or very late preterm periods".[15]